The companies Kailera Therapeutics, Summit Therapeutics, and Tubulis bagged the biggest biotech funding rounds overall in October 2025.

Pichia pastoris is emerging as a versatile, efficient alternative for protein production, bridging microbial and mammalian expression systems.

From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

A deficiency of dopamine: how does Parkinson’s disease affect the body? Unlike levodopa, which, when it reaches the brain gets converted to dopamine, the drug in question, tavapadon, activates ...

Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...

What if the key to a greener future wasn’t in high-tech gadgets or sweeping legislation, but in mushrooms, plant cells, and even food waste? As the world scrambles to combat climate change and reduce ...

The advent of CRISPR gene editing has enabled the creation of gene drives, a technology that can increase the odds of a certain gene being inherited. While the technology could help us tackle malaria ...

An unsustainable demand for meat has led to companies looking for alternative solutions to conventional farming methods in order to change the way we eat and think about meat. For biotech companies in ...

On average, it takes 10.5 years for a drug to advance from phase 1 clinical trial to regulatory approval and market access. Between 2010 and 2020, the overall likelihood of approval was 7.9%. These ...